Tactile Systems Technology, Inc. (TCMD)

Tactile Systems Technology's stock has experienced several events in the past six months. The company's Q1 2025 earnings missed expectations, causing a stock price decrease, but Q2 2025 earnings surpassed estimates, driven by Lymphedema and Afflovest product strength. Analysts adjusted price targets following the Q2 report. The stock rose by 6.41% over the last six months, but year-to-date, TCMD shares have lost approximately 43.7% compared to the S&P 500's gain as of August 2025. In August 2025, the stock overtook its 20-day and 50-day moving averages.

The provided search results do not contain explicit information regarding the demand seasonality for Tactile Systems Technology, Inc.'s products and services.

Tactile Systems Technology, Inc., also known as Tactile Medical, is a medical technology company focused on at-home therapies for chronic conditions in vascular disease, oncology, and chronic respiratory conditions. Its main products include the Flexitouch Plus system for lymphedema treatment, the Entre system for venous disorders, AffloVest for pulmonary secretion treatment, Nimbl for upper extremity lymphedema, and Kylee, a mobile app for lymphedema management.

Tactile Systems Technology, Inc. is headquartered in Minneapolis, Minnesota, and incorporated in Delaware. The company's sales are primarily generated within the United States.

Tactile Systems Technology has focused on product innovation and clinical evidence, which generally supports a positive brand reputation. The company launched the Flexitouch Plus with ComfortEase™ and Bluetooth and the Kylee mobile app. Tactile Medical emphasizes its investment in clinical studies to demonstrate the efficacy and value of its products. However, a class-action lawsuit alleging misleading statements and illicit sales activities could negatively impact the company's reputation.

As of September 2025, institutional ownership in Tactile Systems Technology was 0.2%, a decrease from 90.5% in June 2025. Public companies and individual investors hold 53.62% of the company, while insiders hold 3.85% and mutual funds hold 20.35%. Major institutional holders include VOYA INVESTMENT MANAGEMENT LLC, 1620 INVESTMENT ADVISORS, INC., and GAMMA Investing LLC.